Development asset linked to Beijing Luzhu Biopharmaceutical in public FDA and regional records.
biotech · Locally Advanced Breast Cancer (LABC) · Mantle Cell Lymphoma
Beijing Luzhu Biopharmaceutical
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Beijing Luzhu Biopharmaceutical drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Beijing, CN HQ
2 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Beijing, CN
- Employees
- 2
- Programs
- 7
- Drugs
- 5
- Patents
- 0
Beijing Luzhu Biopharmaceutical pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Beijing Luzhu Biopharmaceutical drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Beijing Luzhu Biopharmaceutical in public FDA and regional records.
-
Development asset linked to Beijing Luzhu Biopharmaceutical in public FDA and regional records.
-
Development asset linked to Beijing Luzhu Biopharmaceutical in public FDA and regional records.
-
Development asset linked to Beijing Luzhu Biopharmaceutical in public FDA and regional records.